Fig. 3From: Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohortSurvival analysis according to mutational status. a Progression-free survival (PFS) in SOCS1-mutated and non-mutated cases. b–d Comparison of overall survival (OS), PFS, and event-free survival (EFS) in CREBBP- or EP300-mutated and wild-type cases. e–f Separation between cases with good and bad prognosis was further increased by combining CREBBP or EP300 mutational status and FOXP1 protein overexpression. g–i Prognostic significance of ATM mutations in GCB–DLBCLBack to article page